Login
Companies $VTGN
$0.17 -$0.01 (6.57%) After hours
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc.

vistagen.com

What Do They Do?

Develops intranasal drug candidates for patients with social anxiety, depression, and menopausal hot flashes.

How Do They Make Money?

The company earns sublicense and other revenue under agreements with AffaMed and Fuji Pharma. It can earn an upfront license fee when a partner can use licensed intellectual property, or earn revenue over time when a license is bundled with research services.

FY2026 revenue

Who Are Their Customers?

AffaMed and Fuji Pharma are parties to agreements that generate sublicense and other revenue.

Do Revenues Turn Into Profits?

No. It lost $69.7M in FY2026.

Operating income, FY2026
−5684% of revenue
▼ −29% (Loss) vs FY2025 (−$56M, −11517%)
Net income, FY2026
−5491% of revenue
▼ −36% (Loss) vs FY2025 (−$51.4M, −10580%)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q2 FY2027, the three months to Sep 30, 2026
Revenue
▼ −47%
vs $258K in Q2 FY2026
Net income
▲ +45% (Loss)
vs −$19.4M in Q2 FY2026

Growing. Revenue grew 14% in 4 years, from $1.1M in FY2022 to $1.3M in FY2026, about 3% a year.

Expanded women's health use The older report lists menopausal hot flashes and migraine for a pherine candidate; the latest also describes refisolone for premenstrual dysphoric disorder.

Who Do They Compete With?

Competes with Vanda Pharmaceuticals, Tonix Pharmaceuticals, Sensorium Therapeutics, Engrail Therapeutics, Axsome Therapeutics, Definium Therapeutics, Xenon Pharmaceuticals, Johnson & Johnson, Usona Institute, Neumora Therapeutics, Boehringer Ingelheim, Syndeio Biosciences, Suven Life Sciences, GH Research, Draig Therapeutics, HMNC Brain Health, Sirtsei Pharmaceuticals, Astellas Pharma, Bayer, and Gedeon Richter

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support